AtriCure
AtriCure is a publicly traded medical device company that develops and sells surgical ablation, left atrial appendage exclusion, and cryo nerve block devices used by cardiac surgeons and hospitals globally to treat atrial fibrillation and post-operative pain.
- Company typePublic
- Founded2000
- HeadquartersWest Chester, United States
- Headcount1,001–5,000
- GTM typeB2B
- OfferingHardware or Manufacturing
What AtriCure does
AtriCure, Inc. (NASDAQ: ATRC) is a Mason, Ohio-based medical device company founded in 2000 that develops, manufactures, and sells proprietary devices for the surgical treatment of atrial fibrillation (Afib) and post-operative pain management. The company sells directly to hospitals, cardiac surgeons, electrophysiologists, cardiologists, and anesthesia providers across North America, Europe & Middle East, Asia Pacific, and Canada/Central & South America, with over 1 million patients treated and 750,000+ AtriClip devices sold worldwide. Its revenue is generated almost entirely from hardware sales of surgical ablation systems, left atrial appendage (LAA) exclusion devices, and cryoablation probes through direct enterprise hospital sales.
AtriCure's technology portfolio spans bipolar radiofrequency ablation (Isolator Synergy clamps and pens), cryoablation (cryoICE, cryoFORM, cryoSPHERE probes), pulsed field ablation combined with RF ablation in its newly launched Dual Energy Platform, and the AtriClip family of LAA exclusion devices. The company also offers the EPi-Sense system for Hybrid AF Therapy, the only FDA-approved minimally invasive treatment for long-standing persistent AF, and Cryo Nerve Block Therapy as a non-opioid post-operative pain management approach. Supporting infrastructure includes the Multifunctional Ablation Generator (MAG), the ORLab intraoperative sensing system, and a full suite of minimally invasive surgical instruments.
The business model is a direct enterprise field sales motion targeting hospital procurement and cardiac surgery programs, supplemented by extensive physician education and training programs (in-person courses, CME-accredited modules, STS/HRS-endorsed courses), peer-to-peer surgeon training led by key opinion leaders, and patient-facing disease education through the ACT Against Afib initiative. The company operates a global commercial organization with regional offices in Amsterdam, Netherlands and Minneapolis/Minnetonka, Minnesota, and an exclusive China distribution partnership with Baheal Group established in 2018. AtriCure has been publicly traded since its 2005 IPO and reported FY2025 revenue of approximately $534.5 million (+14.9% YoY) with 75% gross margins and 12-14% growth guidance for 2026 toward a $1 billion Vision 2030 target.
AtriCure firmographics
Firmographics- Name
- AtriCure
- Legal name
- AtriCure, Inc.
- Website
- https://atricure.com
- Company type
- Public
- Founded year
- 2000
- Operating status
- Operating
- Headcount range
- 1,001–5,000 employees
- Short description
- AtriCure is a publicly traded medical device company that develops and sells surgical ablation, left atrial appendage exclusion, and cryo nerve block devices used by cardiac surgeons and hospitals globally to treat atrial fibrillation and post-operative pain.
- Ownership category
- akta.pro rank
AtriCure industry classification
Industry- Product category
- Cardiac Surgical Ablation and Left Atrial Appendage Management Devices
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Surgical and Medical Instrument Manufacturing (339112), Surgical Appliance and Supplies Manufacturing (339113)
- SIC
- Surgical & Medical Instruments & Apparatus (3841), Electromedical & Electrotherapeutic Apparatus (3845)
- akta.pro primary industry
- Electrophysiology Mapping & Ablation Systems (HLAHAFAD)
- akta.pro secondary industries
- Interventional Cardiology (PCI/Structural Heart) (HLAKABAB), Cardiac Assist & Heart Failure Therapies (Implantables, Neuromodulation) (HLAHAFAL), Endoscopic Therapeutic & Access Devices (Trocars, dilators, biopsy/ablation tools) (HLAHADAN), Pain Management (Spine & Musculoskeletal) (HLAKALAM)
Keywords
Where AtriCure is headquartered
LocationHeadquarters
- HQ city
- West Chester
- HQ country
- United States
- HQ region
- North America
Offices6 records
Markets served
AtriCure business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Operations, Technology or R&D, Marketing or Sales, Supply Chain, Infrastructure
Revenue model
- Medical Device Sales (Surgical Ablation & LAA Management): AtriCure generates revenue primarily through the sale of proprietary medical devices including the AtriClip LAA exclusion system, Isolator Synergy ablation clamps, cryoICE cryoablation probes, EPi-Sense hybrid ablation systems, and related surgical instruments. The company sells directly to hospitals and cardiac surgery programs. Revenue is driven by procedure volumes in cardiac surgery (CABG, valve procedures) and growing adoption of surgical ablation and LAA management.
Go-to-market motion2 records
Distribution channels2 records
Marketing channels11 records
AtriCure product offering
Product offeringCore offering
AtriCure develops, manufactures, and sells proprietary medical devices for the surgical treatment of atrial fibrillation (Afib) and post-operative pain management. Core revenue-generating products are the AtriClip Left Atrial Appendage Exclusion System (multi-variant family including PRO-Mini, FLEX-Mini, FLEX-V, PRO-V, PRO2, PRO), the Isolator Synergy Bipolar Radiofrequency Ablation system (clamps, pens, Coolrail, Lumitip Dissection and Multifunctional Ablation Generator) for concomitant surgical ablation, the cryoICE cryoablation platform supporting Cryo Nerve Block Therapy, and the EPi-Sense based Hybrid AF Therapy for long-standing persistent AF. Products are sold directly to hospitals, cardiac surgeons, electrophysiologists, and cardiac surgery programs across more than 50 countries through a dedicated regional direct-sales organization.
Product overview
AtriCure is a medical device company offering a comprehensive portfolio of products for atrial fibrillation (Afib) treatment and post-operative pain management. The product portfolio centers on three main platforms: (1) Concomitant Surgical Ablation Therapy including Isolator Synergy bipolar RF ablation clamps and pens, Coolrail Linear Pen, and Multifunctional Ablation Generator for cardiac tissue ablation during surgery; (2) Left Atrial Appendage Management with the AtriClip family of devices (FLEX-Mini, PRO-Mini, FLEX-V, PRO-V, PRO2, PRO) for stroke prevention; and (3) Cryo Nerve Block Therapy using cryoSPHERE MAX, cryoSPHERE+, and cryoXT probes for opioid-sparing post-surgical pain management. Additional offerings include Hybrid AF Therapy combining EPi-Sense epicardial-endocardial devices for minimally invasive Afib treatment, and a Dual Energy Platform combining Pulsed Field Ablation and Radiofrequency Ablation technologies. The company also provides comprehensive minimally invasive surgical instruments. Over 750,000 patients have been served with AtriClip devices and over 1 million patients treated with ablation products worldwide.
Differentiator
Problem solved
Functional benefit
Products and services
- AtriClip Left Atrial Appendage (LAA) Exclusion System Multi-variant family of closed-ended LAA management devices providing mechanical and electrical isolation of the left atrial appendage to reduce stroke risk in atrial fibrillation patients. The family includes AtriClip PRO, PRO2, PRO-V, PRO-Mini, FLEX, FLEX-V, and FLEX-Mini variants, designed for concomitant surgical procedures including open cardiac surgery and minimally invasive approaches; FLEX-Mini is the smallest surgical LAAM device available. Over 750,000 patients have been served with AtriClip devices worldwide.
- Isolator Synergy Bipolar Radiofrequency (RF) Ablation System Bipolar RF ablation system for concomitant surgical ablation during cardiac surgery, including Isolator Synergy clamps (OLL2/OSL2), the Synergy EnCompass Clamp for non-atriotomy procedures, the Isolator Synergy Access Clamp for hybrid total thoracoscopic procedures, Isolator Linear Pen, Transpolar Pens (MAX1, MAX5), Coolrail Linear Pen, and the Lumitip Dissection System. Uses proprietary Synergy algorithm and energy delivery for customized RF energy output during lesion sets such as Cox-Maze IV, pulmonary vein isolation, Box lesion, and posterior wall isolation.
- Multifunctional Ablation Generator (MAG) Ablation generator platform supporting multiple ablation modalities for surgical ablation procedures.
- Hybrid AF Therapy (EPi-Sense Guided Coagulation System) Minimally invasive two-stage solution combining epicardial and endocardial ablation for long-standing persistent atrial fibrillation. Includes the EPi-Sense device and EPi-Sense ST device (released 2023). FDA-approved for treatment of long-standing persistent AF, with hybrid ablation demonstrating up to 88% freedom from atrial arrhythmias and 94% reduction in AF burden to ≤5%, and 2x greater effectiveness than catheter ablation alone.
- Cryo Nerve Block Therapy Platform (cryoICE) Non-opioid post-operative pain management approach using cryoablation probes to target peripheral nerves. Includes the cryoICE BOX V6 generator and probes—cryoICE, cryoFORM, cryoSPHERE+, cryoSPHERE MAX, and cryoXT—for Cryo Nerve Block Therapy in thoracic surgery, transitional pain, amputation pain management, and cardiac tissue ablation.
- EPi-Ease Epicardial Access Device Device for epicardial access supporting hybrid ablation procedures.
- ORLab System Intraoperative system for ablation verification and monitoring during surgical ablation procedures.
- Ablation Sensing Unit & Switch Matrix Sensing and energy delivery management equipment used during surgical ablation procedures.
- Minimally Invasive Surgical Instruments Suite of surgical instruments for minimally invasive cardiac procedures, including the Atrial Lift System, graspers, needle holders, retractors and blades, scissors, rakes and valve assistants, and accessories.
- Dual Energy Platform (PFA + RFA) Novel platform combining Pulsed Field Ablation (PFA) and Advanced Radiofrequency Ablation (RFA) technologies capable of ablation in less than 60 seconds. First successful treatments performed at the Victorian Heart Hospital in Australia in December 2025, with plans for a clinical trial.
Quantifiable outcome
- Up to 90% freedom from atrial fibrillation with Cox-Maze IV surgical ablation procedure
- +8 more outcomes
Companies that use AtriCure
Customer profileNamed customers1 record
Segments7 records
Ideal customer profiles3 records
AtriCure technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature12 records
AtriCure partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Baheal GroupcoreAtriCure and Baheal Group established a partnership and China distribution agreement in 2018. Baheal Group serves as AtriCure's exclusive distribution partner for the China market, distributing AtriClip and cryoICE products. China represents a significant growth market for cardiac ablation and LAA management given the large Afib patient population.
Scale indicators7 records
Recent moves8 records
Expansion highlights6 records
AtriCure competitors and assessment
Company assessmentDirect peers
- Boston Scientific: Boston Scientific is a leading competitor in atrial fibrillation treatment with its catheter-based ablation portfolio including the FARAPULSE pulsed field ablation system. It competes with AtriCure in the Afib ablation market though primarily via catheter-based rather than surgical approaches.
- Medtronic: Medtronic is a major player in cardiac ablation through its CryoCath cryoablation and PulseSelect pulsed field ablation systems. As one of the largest medical device companies globally, it competes with AtriCure across cardiac surgery and catheter ablation for Afib.
- Abbott: Abbott competes in the Afib treatment space through its cardiac ablation portfolio and structural heart devices. It is explicitly identified as a competitive threat in the global ablation technology market alongside Medtronic, Boston Scientific, and J&J.
- Johnson & Johnson (Biosense Webster): Biosense Webster, a Johnson & Johnson company, is a global leader in electrophysiology and catheter ablation for atrial fibrillation with the CARTO mapping system and extensive ablation catheter portfolio. It competes directly with AtriCure in the Afib ablation market.
- CONMED: CONMED is a medical device company with a cardiac surgery and ablation portfolio that overlaps with AtriCure's surgical ablation business. It is a smaller competitor but addresses similar hospital customers with overlapping product categories.
Emerging players
- Edwards Lifesciences: Edwards Lifesciences has announced plans to enter the surgical left atrial appendage closure (LAAC) market in 2026, directly challenging AtriCure's AtriClip franchise. As a leading structural heart player, Edwards brings significant resources and hospital relationships.
- AngioDynamics: AngioDynamics manufactures medical devices for vascular access and ablation therapies, including NanoKnife irreversible electroporation and other ablation technologies. It competes in adjacent ablation markets with overlapping cardiology applications.
- Stereotaxis: Stereotaxis develops robotic magnetic navigation systems for cardiac ablation procedures, enabling precise catheter-based ablation for arrhythmias. It represents a technology approach that competes with both catheter and surgical ablation in the Afib treatment market.
- Adagio Medical: Adagio Medical develops cryoablation technologies for atrial fibrillation, including ultra-low temperature cryoablation catheters. It is a smaller, emerging player competing in the same Afib ablation space as AtriCure's cryoablation products.
- Kardium: Kardium is developing the Globe PF System, a pulsed field ablation system for atrial fibrillation. As an emerging player in PFA technology, it competes with both catheter-based PFA systems and indirectly with AtriCure's emerging Dual Energy PFA+RFA platform.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
AtriCure social profiles
Digital presenceAtriCure financial estimates
Financial estimateRevenue estimate
Valuation estimate
AtriCure leadership team
Management profileNumber of profiles
Profiles6 records
AtriCure subsidiaries and ownership
Company hierarchySubsidiaries3 records
AtriCure funding detail
Funding detailFunding overview
Funding rounds4 records
Investors5 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
AtriCure M&A and investment
M&A and investmentM&A3 records
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about AtriCure
What does AtriCure do?
AtriCure develops, manufactures, and sells proprietary medical devices for the surgical treatment of atrial fibrillation (Afib) and post-operative pain management. Core revenue-generating products are the AtriClip Left Atrial Appendage Exclusion System (multi-variant family including PRO-Mini, FLEX-Mini, FLEX-V, PRO-V, PRO2, PRO), the Isolator Synergy Bipolar Radiofrequency Ablation system (clamps, pens, Coolrail, Lumitip Dissection and Multifunctional Ablation Generator) for concomitant surgical ablation, the cryoICE cryoablation platform supporting Cryo Nerve Block Therapy, and the EPi-Sense based Hybrid AF Therapy for long-standing persistent AF. Products are sold directly to hospitals, cardiac surgeons, electrophysiologists, and cardiac surgery programs across more than 50 countries through a dedicated regional direct-sales organization.
Is AtriCure a public or private company?
AtriCure is a public company. It is classified as public and is currently operating.
When was AtriCure founded?
AtriCure was founded in 2000. It employs 1,001 to 5,000 people.
Where is AtriCure based?
AtriCure is headquartered in West Chester, United States, in the North America region.
How does AtriCure make money?
One revenue line is on record: medical Device Sales (Surgical Ablation & LAA Management).
Who are AtriCure's main competitors?
Direct peers on record are Boston Scientific, Medtronic, Abbott, Johnson & Johnson (Biosense Webster) and CONMED. Emerging players are Edwards Lifesciences, AngioDynamics, Stereotaxis, Adagio Medical and Kardium.
Does AtriCure have an API?
No public API is recorded for AtriCure.
What industry is AtriCure in?
AtriCure's product category is Cardiac Surgical Ablation and Left Atrial Appendage Management Devices. Its primary akta.pro industry code is HLAHAFAD, Electrophysiology Mapping & Ablation Systems, with a secondary code of HLAKABAB, Interventional Cardiology (PCI/Structural Heart). Its NAICS code is 334510 and its SIC code is 3841.